Primary Central Nervous System Lymphoma

Neurologic Clinics

Volumn 25, Issue 4, 2007, Pages 1193-1207

  Mohile, Nimish A ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CORTICOSTEROID; CYTARABINE; IDARUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ACUTE TOXICITY; ATAXIA; BEHAVIOR CHANGE; BRAIN SURGERY; CHEMOSENSITIVITY; CHRONIC TOXICITY; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; HUMAN; LETHARGY; MENTAL HEALTH; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOMNOLENCE; URINE INCONTINENCE;

ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA; NEUROSURGICAL PROCEDURES; PROGNOSIS; SALVAGE THERAPY;

EID: 35348967778     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.07.001     Document Type: Review

References (65)

1. DeAngelis L.M., Gutin P.H., Leibel S.A., et al. Intracranial tumors. Diagnosis and treatment. 1st edition (2002), Martin Dunitz, London
2. Ferreri A.J.M., Abrey L.E., Blay J.-Y., et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21 12 (2003) 2407-2414
3. Shenkier T.N., Blay J.-Y., O'Neill B.P., et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23 10 (2005) 2233-2239
4. Jahnke K., Hummel M., Korfel A., et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24 29 (2006) 4754-4757
5. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 43 3 (1999) 199-201
6. Coté T.R., Manns A., Hardy C.R., et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 88 10 (1996) 675-679
7. Eby N.L., Grufferman S., Flannelly C.M., et al. Increasing incidence of primary brain lymphoma in the US. Cancer 62 11 (1988) 2461-2465
8. Olson J.E., Janney C.A., Rao R.D., et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95 7 (2002) 1504-1510
9. Corn B.W., Marcus S.M., Topham A., et al. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer 79 12 (1997) 2409-2413
10. Hao D., DiFrancesco L.M., Brasher P.M., et al. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann Oncol 10 1 (1999) 65-70
11. Kadan-Lottick N.S., Skluzacek M.C., and Gurney J.G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95 1 (2002) 193-202
12. Panageas K.S., Elkin E.B., DeAngelis L.M., et al. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 104 11 (2005) 2466-2472
13. Pollack I.F., Lunsford L.D., Flickinger J.C., et al. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63 5 (1989) 939-947
14. Corry J., Smith J.G., Wirth A., et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41 3 (1998) 615-620
15. Blay J.Y., Lasset C., Carrie C., et al. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer 67 5 (1993) 1136-1141
16. Ferreri A.J.M., Blay J.-Y., Reni M., et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 2 (2003) 266-272
17. Abrey L.E., Ben-Porat L., Panageas K.S., et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 36 (2006) 5711-5715
18. Küker W., Nägele T., Korfel A., et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72 2 (2005) 169-177
19. Abrey L.E., Batchelor T.T., Ferreri A.J.M., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 22 (2005) 5034-5043
20. DeAngelis L.M., Yahalom J., Thaler H.T., et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10 4 (1992) 635-643
21. O'Neill B.P., Dinapoli R.P., Kurtin P.J., et al. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?. J Neurooncol 25 1 (1995) 67-71
22. Mohile N., DeAngelis L., and Abrey L. The role of cranial and body 18 fluoro-deoxyglucose positron emission tomography in primary CNS lymphoma. Proceedings of the American Society of Clinical Oncology 24 (2006) 665
23. Todd F.D., Miller C.A., Yates A.J., et al. Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg Neurol 26 1 (1986) 79-84
24. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 43 3 (1999) 237-239
25. Lai R., Rosenblum M.K., and DeAngelis L.M. Primary CNS lymphoma: a whole-brain disease?. Neurology 59 10 (2002) 1557-1562
26. Shibamoto Y., Hayabuchi N., Hiratsuka J.-I., et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97 1 (2003) 128-133
27. Blay J.Y., Conroy T., Chevreau C., et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16 3 (1998) 864-871
28. Nelson D.F., Martz K.L., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 1 (1992) 9-17
29. Bessell E.M., López-Guillermo A., Villá S., et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 1 (2002) 231-236
30. Abrey L.E., Yahalom J., and DeAngelis L.M. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18 17 (2000) 3144-3150
31. Gavrilovic I.T., Hormigo A., Yahalom J., et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24 28 (2006) 4570-4574
32. Yahalom J., and Abrey L.E. Reduced-dose whole grain radiotherapy (WBRT) following complete response to immuno-chemotherapy in patients with primary CNS lymphoma (PCNSL). ASTRO Abstract 66 6 (2006) 584
33. Lachance D.H., Brizel D.M., Gockerman J.P., et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44 9 (1994) 1721-1727
34. Schultz C., Scott C., Sherman W., et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14 2 (1996) 556-564
35. Shibamoto Y., Tsutsui K., Dodo Y., et al. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65 9 (1990) 1907-1912
36. Brada M., Dearnaley D., Horwich A., et al. Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 18 4 (1990) 787-792
37. Skarin A.T., Zuckerman K.S., Pitman S.W., et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50 6 (1977) 1039-1047
38. Ferreri A.J.M., Guerra E., Regazzi M., et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90 2 (2004) 353-358
39. Slevin M.L., Piall E.M., Aherne G.W., et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1 9 (1983) 546-551
40. Hiraga S., Arita N., Ohnishi T., et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91 2 (1999) 221-230
41. Khan R.B., Shi W., Thaler H.T., et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 58 2 (2002) 175-178
42. Shapiro W.R., Young D.F., and Mehta B.M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293 4 (1975) 161-166
43. Omuro A.M.P., Ben-Porat L.S., Panageas K.S., et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62 10 (2005) 1595-1600
44. Cheng A.L., Yeh K.H., Uen W.C., et al. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 82 10 (1998) 1946-1951
45. DeAngelis L.M., Seiferheld W., Schold S.C., et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 24 (2002) 4643-4648
46. Ferreri A.J.M., Dell'Oro S., Foppoli M., et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66 9 (2006) 1435-1438
47. Omuro A.M.P., DeAngelis L.M., Yahalom J., et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64 1 (2005) 69-74
48. Poortmans P.M.P., Kluin-Nelemans H.C., Haaxma-Reiche H., et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 24 (2003) 4483-4488
49. Bessell E.M., Graus F.F., Lopez-Guillermo A., et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59 2 (2004) 501-508
50. Guha-Thakurta N., Damek D., Pollack C., et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43 3 (1999) 259-268
51. Batchelor T., Carson K., O'Neill A., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21 6 (2003) 1044-1049
52. Milpied N., Deconinck E., Gaillard F., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 13 (2004) 1287-1295
53. Abrey L.E., Moskowitz C.H., Mason W.P., et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21 22 (2003) 4151-4156
54. Cheng T., Forsyth P., Chaudhry A., et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 8 (2003) 679-685
55. Illerhaus G., Marks R., Ihorst G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 24 (2006) 3865-3870
56. Neuwelt E.A., Goldman D.L., Dahlborg S.A., et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9 9 (1991) 1580-1590
57. Arellano-Rodrigo E., López-Guillermo A., Bessell E.M., et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70 4 (2003) 219-224
58. Herrlinger U., Brugger W., Bamberg M., et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54 8 (2000) 1707-1708
59. Pels H., Schulz H., Schlegel U., et al. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26 4 (2003) 351-354
60. Reni M., Mason W., Zaja F., et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40 11 (2004) 1682-1688
61. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 3 (2001) 742-749
62. Enting R.H., Demopoulos A., DeAngelis L.M., et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 5 (2004) 901-903
63. Correa D., DeAngelis L.M., Shi W., et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62 4 (2004) 548-555
64. Lai R., Abrey L.E., Rosenblum M.K., et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62 3 (2004) 451-456
65. Thiessen B., and DeAngelis L.M. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 55 5 (1998) 705-710